[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut Curie\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":673},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,43,75,110,141,169,193,216,241,264,293,316,348,374,405,428,456,482,508,529,556,581,609,630,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100620463","omission-of-surgery-for-triple-negative-breast-cancer-in-complete-response-after-neoadjuvant-chemo-immunotherapy-100620463",false,"NCT07357948","Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy","Omission of Surgery for Triple-negative Breast Cancer in Complete Response Confirmed by MRI and Macrobiopsy After Neoadjuvant Chemo-immunotherapy: a Randomized, Multicenter Phase II Trial.","OMICHIR","Inclusion Criteria:\n\n1. Sex and age: Female, aged 18 years or older.\n2. Histological type: Invasive breast carcinoma of no special type (NST).\n3. Triple-negative phenotype, defined by:\n\n   * Estrogen receptor (ER) \\\u003C 10%,\n   * Progesterone receptor (PR) \\\u003C 10%,\n   * HER2-negative status according to ASCO\u002FCAP criteria (IHC score 0-1+, or 2+ without amplification by in situ hybridization).\n4. High proliferation index: Ki-67 \\> 30%.\n5. Primary tumor classified as T2, i.e. tumor size between 2 and 5 cm on imaging at diagnosis (mammography, ultrasound, and breast MRI).\n6. No regional lymph node involvement or distant metastasis, confirmed by 18F-FDG PET-CT performed prior to neoadjuvant treatment.\n7. Completion of the full neoadjuvant chemo-immunotherapy (NCIT) protocol according to the KEYNOTE-522 regimen (≥7 cycles including pembrolizumab).\n8. Breast-conserving surgery deemed feasible based on the initial surgical assessment.\n9. Radiological complete response (rCR) on post-NCIT breast MRI, associated with a negative vacuum-assisted biopsy (VAB) of the clip-marked tumor bed, confirming the absence of residual invasive or in situ disease.\n10. Written informed consent obtained prior to any study-specific procedure.\n11. Ability of the patient to comply with the protocol requirements and scheduled follow-up.\n12. Affiliation with a national health insurance system, in accordance with French regulations.\n\nExclusion Criteria:\n\n1. Presence of regional recurrence or metastatic disease at inclusion.\n2. History of thoracic, breast, or regional lymph node irradiation, regardless of indication.\n3. Invasive lobular carcinoma, excluded due to its different response profile and increased risk of multifocal residual disease.\n4. Presence of ductal carcinoma in situ (DCIS) on diagnostic biopsy, or diffuse suspicious microcalcifications on mammography, precluding reliable assessment of complete response.\n5. Bilateral breast cancer (except for localized and treated contralateral DCIS), or history of ipsilateral or contralateral invasive breast cancer.\n6. Multifocal or multicentric disease detected on imaging (mammography, ultrasound, or breast MRI).\n7. Skin involvement or inflammatory breast cancer, identified on imaging or clinical examination.\n8. History of malignancy other than breast cancer, unless the disease has been in complete remission for ≥ 5 years and is considered at low risk of recurrence, with the exception of:\n\n   * Treated carcinoma in situ of the cervix, endometrium, or colon,\n   * Melanoma in situ,\n   * Completely excised cutaneous basal cell or squamous cell carcinoma.\n9. Severe or progressive non-malignant disease limiting life expectancy to less than 10 years, in the investigator's judgment.\n10. Presence of a high-risk germline mutation predisposing to breast cancer (including BRCA1, BRCA2, or other identified predisposition genes).\n11. Participation in another interventional clinical trial within 30 days prior to inclusion.\n12. Current pregnancy or breastfeeding.\n13. Cognitive impairment, psychiatric disorder, or social situation preventing valid informed consent or adequate understanding of the protocol, as assessed by the investigator.\n14. Individuals deprived of liberty or under legal protection (guardianship, curatorship, or similar legal status), in accordance with applicable regulations.","FEMALE","18 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer patients in complete response after neoadjuvant chemo-immunotherapy.\n\nPatients will be randomised into 2 groups :\n\n* Control arm will receive the standard treatment, including surgery\n* Experimental arm will receive the standard treatment, except surgery",[28,29],"Triple Negative Breast Cancer","Non-Metastatic","NOT_YET_RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":22},"2026-08-01",{"date":38,"type":22},"2033-07-31",{"name":40,"class":41},"Institut Curie","OTHER",4,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100549887","optimizing-bronchopulmonary-cancer-screening-100549887","NCT06439901","Optimizing Bronchopulmonary Cancer Screening","Optimizing the Implementation of Bronchopulmonary Cancer Screening in the Ile de France Region (OPTI-DEPIST-MUT)","OPTI-DEPIST","Inclusion Criteria:\n\n* Participant aged 50 to 74.\n* Resident in the Île-de-France region.\n* Active smoker or quit smoker for 10 years or less:\n\n  1. more than 10 cigarettes a day for more than 30 years,\n  2. more than 15 cigarettes a day for more than 25 years.\n* The participant has been informed and has signed the consent form.\n* Social Security System affiliation.\n* Willingness to participate in a smoking cessation program, if currently smoking.\n\nExclusion Criteria:\n\n* Active cancer or a history of cancer in remission for less than 5 years (except basal cell carcinoma of th skin or epithelioma in situ of the uterine cervix).\n* Presence of symptoms suggestive of bronchopulmonary cancer. Participants with these symptoms require immediate diagnostic investigations and are therefore not eligible for screening.\n* Weight \\>= 140 kg.\n* Severe comorbidity contraindicating therapeutic options or invasive thoracic diagnostic investigations.\n* Inability to climb two flights of stairs without stopping.\n* A thoracic CTscan performed within the previous year.\n* Persons deprived of liberty or under guardianship.\n* Impossibility to undergo the medical monitoring of the trial for geographical, social or psychological reasons.","ALL","50 Years","74 Years",{"count":55,"type":22},500,[25],"The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and structured network in the pilot centers participating in the study.",[59,60],"Bronchopulmonary Disease","Diagnoses Disease",[62,63,64],"bronchopulmonary cancer","screening","primary prevention","RECRUITING","2026-05-29",{"date":68,"type":34},"2026-06-02",{"date":70,"type":34},"2025-01-27",{"date":72,"type":22},"2034-02-05",{"name":40,"class":41},8,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100185446","cosegregation-of-variants-in-panel-of-genes-100185446","NCT01689584","COsegregation of VARiants in Panel of Genes","Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling","COVAR","Inclusion Criteria:\n\nIndex cases:\n\n* A person carrying a variant of interest in a gene analyzed in a diagnostic setting by one of the laboratories within the Genetics and Cancer Group (GGC)-Unicancer network, classified as class 3, 4 or hypomorphic class 5, and selected by the national expert group for the gene concerned.\n* Age ≥ 18 years.\n* Signed written inform consent \"index case\"\n\nRelated parties:\n\n* Any relative of an index case with cancer\n* Any relative without cancer related to an index case, selected by the investigators, according to family structure and degree of related compared to the index case\n* For class 4 and hypomorphic class 5 variants; relatives currently undergoing analysis or having already obtained a test result for the variant of interest as part of clinical care.\n* Age ≥ 18 years\n* Information and signature of the informed consent \"selected relatives\"\n\nExclusion Criteria:\n\n* Minors\n* Persons deprived of liberty or under guardianship (including curators).\n* Absence of signed written inform consent",{"count":84,"type":22},11000,[25],"The aim of the COVAR project is to achieve reliable classification of as many variants of interest as possible from the French OncoGenetics Database (FrOG, https:\u002F\u002Ffrog-db.fr\u002F) in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some cases to propose a prophylactic surgery.",[88,89],"Gene Mutation-Related Cancer","Genetic Predisposition",[91,92,93,94,95,96,97,98,99,100],"BRCA1","BRCA2","VUS","co-segregation","genetic counseling","PALB2","panel of genes","variant","hypomorphic","Hereditary cancer (breast, ovarian, prostate, pancreas, digestive track)","2026-05-22",{"date":103,"type":34},"2026-05-27",{"date":105,"type":34},"2012-07-02",{"date":107,"type":22},"2038-01-02",{"name":40,"class":41},62,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100636890","adherence-to-enteral-nutrition-100636890","NCT07571564","Adherence to Enteral Nutrition","ADHENUTE","Inclusion Criteria:\n\n* Patients hospitalized (including those in the day hospital) in a medical oncology unit;\n* Adults;\n* Men or women;\n* Patients for whom enteral nutrition is indicated according to SFNCM recommendations;\n\nExclusion Criteria:\n\n* Minors (under 18 years of age)\n* Patients receiving end-of-life palliative care\n* Individuals deprived of their liberty or under legal guardianship (including conservatorship);\n* Adults under judicial protection;\n* Inability to participate in the study for geographical, social, or psychological reasons.\n* Persons referred to in Articles L. 1121-5 through L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g., minors, adults under guardianship, etc.).\n* Patients who do not speak or understand French.","100 Years",{"count":119,"type":22},80,"OBSERVATIONAL","Malnutrition is a major challenge in cancer nutrition, affecting approximately 40% of cancer patients and having negative consequences on treatment efficacy, quality of life, and prognosis. It must be detected and managed early, based on clinical and laboratory criteria defined by the HAS recommendations.\n\nTo address this, several nutritional strategies are available, ranging from fortified oral feeding to artificial nutrition. Enteral nutrition, which is more physiological and carries fewer risks than parenteral nutrition, is recommended as the first-line treatment. Tools such as personalized care plans and guidelines help tailor patient care.\n\nHowever, enteral nutrition remains underutilized in clinical practice, despite the recommendations. The ADHENUTE study, conducted at the Institut Curie, showed low compliance with recommendations (31%) and a tendency to favor oral nutritional supplements, even in severely malnourished patients. The lack of traceability of decisions makes it difficult to identify barriers, although patient refusal is sometimes mentioned.\n\nTo improve this situation, corrective measures have been implemented:\n\n* for patients, through educational workshops to help them better understand and accept enteral nutrition;\n* for healthcare providers, through training sessions to address reservations and enhance knowledge.\n\nA third phase of the study aims to evaluate the impact of these actions, with the goal of increasing adherence to recommendations and the use of enteral nutrition.",[123],"Enteral Nutrition",[125,126,127,128,129,130,131],"enteral nutrition","adherence to enteral nutrition","compliance with enteral nutrition guidelines","malnutrition","nutritional supplements","patient education workshops","training for healthcare staff","2026-04-30",{"date":134,"type":34},"2026-05-06",{"date":136,"type":34},"2026-03-05",{"date":138,"type":22},"2027-09-04",{"name":40,"class":41},1,{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100475779","personalized-first-line-chemotherapy-choice-in-advanced-pancreatic-adenocarcinoma-using-transcriptomic-signatures-100475779","NCT05475366","Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures","Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)","PACsign","Inclusion Criteria:\n\n1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n2. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n3. Histologically or cytologically proven Pancreatic Ductal Adenocarcinoma (PDAC).\n4. Metastatic disease.\n5. Measurable or evaluable lesions according to RECIST v1.1 criteria.\n6. First-line therapy (previous neoadjuvant\u002Fadjuvant chemotherapy not allowed).\n7. Age ≥ 18 years (no upper limit, patients ≥ 75 years old must have a G8 score ≥ 14).\n8. 3\\. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.\n9. Availability of tumor tissue sample from the primary pancreatic tumor or liver metastasis (chemo-naïve) before inclusion in step 1.\n10. Adequate organ function, as defined by the following (blood test ≤ 7 days prior to inclusion):\n\n    1. Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (≤ 5 ULN in case of liver metastases)\n    2. Total serum bilirubin ≤ 1.5 ULN\n    3. Serum albumin ≥ 28 g\u002FL\n    4. Hemoglobin ≥ 9.0 g\u002Fdl\n    5. Absolute neutrophil count (ANC) ≥ 1,500\u002FμL\n    6. Platelets ≥ 100,000\u002FμL\n    7. Creatinine clearance ≥ 50 mL\u002Fmin (MDRD).\n11. No Dihydropyrimidine dehydrogenase (DPD) deficiency (normal uracil level).\n12. Life expectancy ≥ 3 months.\n13. a. Evidence of post-menopausal status b. (or) negative urinary or serum pregnancy test for female pre-menopausal patients.\n14. Registration in a National Health Care System.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another interventional clinical study.\n2. Previous treatment with chemotherapy for pancreatic cancer.\n3. Uncontrolled massive pleural effusion or massive ascites.\n4. Known deficiency in UGT1A1 (homozygous UGT1A1\\*28 allele).\n5. Active bacterial, viral, or fungal infection requiring systemic therapy, including tuberculosis, hepatitis B (known positive Hepatitis B Virus surface antigen (HBsAg) result), hepatitis C (with positive RNA), Sars-Cov-2 or human immunodeficiency virus (positive HIV 1\u002F2 antibodies).\n6. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.\n7. Known active central nervous system metastases and\u002For carcinomatous meningitis; patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline).\n8. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure or coronary disease, peripheral artery disease, severe chronic obstructive pulmonary disease, decompensated cirrhosis, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n9. Live vaccine administration within 30 days prior to the first dose of study treatment.\n10. Known or suspected allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant, in the opinion of the treating investigator.\n12. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.\n13. Major surgical procedure (as defined by the Investigator) within 4 weeks prior to the first dose of trial treatment.\n14. Pregnancy\u002Flactation.\n15. Person under legal protection or tutelage or guardianship.","75 Years",{"count":151,"type":22},85,[25],"The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic signatures applied to the pre-therapeutic liver biopsy of newly diagnosed PDAC patients.",[155,156],"Carcinoma, Pancreatic Ductal","Prognosis",[158,159,160],"Transcriptomic signatures","Personalized first-line chemotherapy","Metastatic PDAC",{"date":162,"type":34},"2026-05-01",{"date":164,"type":34},"2022-12-12",{"date":166,"type":22},"2028-12-11",{"name":40,"class":41},7,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},"100466517","exploration-of-adaptive-antitumoral-immune-cells-through-lymphapheresis-in-cancer-patients--alcyta-100466517","NCT05354765","Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA","ALCYTA","Inclusion Criteria:\n\n1. Patient aged 18 or over,\n2. Patient presenting an invasive tumor pathology (proven or suspected). The location and \u002F or stage of which are defined for each cohort through an amendment to the protocol,\n3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters,\n4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),\n5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement,\n6. Total circulating lymphocytes\\> 1000 \u002F mm3,\n7. Availability of DNA and RNA from the tumor,\n8. Information to the patient and signature of informed consent or his legal representative,\n9. Affiliated with a social security scheme or such a scheme.\n\nExclusion Criteria:\n\n1. Inability to undergo study follow-up for geographical, social or psychological reasons,\n2. Infection with HIV or hepatitis B or C viruses,\n3. Patients on high dose corticosteroid treatment (\\> 1 mg \u002F kg continuously),\n4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease),\n5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.),\n6. Pregnant patient or of childbearing age without effective contraception,\n7. Persons deprived of their liberty, under guardianship or legal protection.",{"count":177,"type":22},300,[25],"The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.",[181,182],"Cancer","Immune System or Toxicities Suspected",[184,185],"tumor-antigen specific immune cells","circulating tumor DNA",{"date":134,"type":34},{"date":188,"type":34},"2022-08-31",{"date":190,"type":22},"2027-09-03",{"name":40,"class":41},2,{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":149,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},"100418661","randomized-multicenter-phase-iii-trial-to-assess-conformal-post-operative-radiotherapy-vs-surveillance-after-complete-resection-of-stage-iiiii-thymoma-radio-rythmic-01-100418661","NCT04731610","Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II\u002FIII Thymoma (RADIO-RYTHMIC-01)","Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II\u002FIII Thymoma","RADIO-RYTHMIC","Inclusion Criteria:\n\n1. 18 \\\u003C Age \\\u003C 75 years old\n2. ECOG performance status ≤1\n3. Preoperative chemotherapy is allowed. Maximum of 4 cycles are authorized. Surgery should be realized ≤ 2 months after the last chemotherapy injection.\n4. Histologically diagnosed thymoma at pathological examination of surgical specimen after pathological review; for note, centralized, real-time, systematic pathological review is standard through the RYTHMIC network in France\n5. Complete resection at pathological examination of the surgical specimen after surgery conducted through standard, recommended approach ensuring accurate assessment of resection status\n6. Stage IIb or III disease according to the Masaoka-Koga staging system; this corresponds to stage pT1a with capsule invasion, until stage pT3 N0 M0 in the 8th TNM staging system TNM UICC\u002FAJCC\n7. Availability of thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of contra-indications) or PET scan performed before surgery\n8. Availability of a thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of contra-indications) showing absence of residual disease after surgical resection of the tumor\n9. Pulmonary function tests after surgery with FEV1 ≥ 1L or ≥ 35% of the theoretical value and DLCO ≥ 40%\n10. Signature of informed consent form\n\nExclusion Criteria:\n\n\\- 1. Age \\> 75 years old 2. Histology of thymic carcinoma 3. Delivery of post-operative chemotherapy, concurrent chemotherapy to radiotherapy 4. Presence of microscopic or macroscopic residual tumor after surgery or metastases (R1 or R2 resection) 5. Uncontrolled, clinically significant pleural or pericardial effusion 6. Patients with prior radiation therapy to the thorax. Patients treated with conformal radiotherapy for prior breast or head and neck neoplasms should be discussed with PI 7. Evidence of severe or uncontrolled systemic disease as judged by the investigator 8. Recent (\\\u003C 6 months) severe cardiac disease (uncontrolled arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease. Controlled and non clinically symptomatic arrhythmia is allowed.\n\n9\\. Current or past history of neoplasm diagnosed within the last 3 years, except: basal cell carcinoma of the skin, in situ carcinoma of the cervix, and bladder in situ. A patient diagnosed for another neoplasm 3 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected 10. Pregnancy or breast feeding or inadequate contraceptive measures for women of childbearing potential during PORT 11. Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and\u002For are incapable of undergoing regular controls, 12. Patients deprived of freedom or under guardianship",{"count":202,"type":22},314,[25],"The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.",[206],"Thymoma Malignant Recurrent","2026-04-17",{"date":209,"type":34},"2026-04-20",{"date":211,"type":34},"2021-12-28",{"date":213,"type":22},"2032-12-28",{"name":40,"class":41},21,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":215},"100531124","phase-3-eclectic-estrotep-and-circulating-biomarkers-for-er-positive-her2-negative-metastatic-breast-cancer-patients-100531124","NCT06195709","ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients","ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients","ECLECTIC","Inclusion Criteria:\n\n1. Metastatic invasive breast carcinoma of no special type.\n2. Females and males of age ≥18 years.\n3. Life expectancy \\> 3 months.\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.\n5. Estrogen Receptor (ER)-positive (≥10%) and HER2-negative (ASCO\u002FCollege of American Pathologists guidelines) breast cancer, per local assessment on the most recent breast cancer tissue examined.\n6. Tumor block Formalin-Fixed Paraffin-Embedded (primary tumor or metastasis) available.\n7. Patients whose disease has progressed on first line endocrine therapy with aromatase inhibitor and CDK4\u002F6 inhibitor and who are deemed eligible, per investigator assessment, to a second line endocrine therapy. The progression on first line endocrine therapy with aromatase inhibitor and CDK4\u002F6 inhibitor must have occurred after more than 6 months on treatment.\n8. Patients with available 18F-FDG PET\u002FCT imaging\n9. Evaluable disease per RECIST criteria and measurable disease per PERCIST criteria.\n10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and any protocol-related procedures including screening evaluations.\n11. Signed informed consent.\n12. Patient affiliated to a social security system.\n\nExclusion criteria:\n\n1. Other breast cancer subtype (e.g. invasive lobular breast carcinoma).\n2. One or more prior line of chemotherapy in the metastatic setting.\n3. Any other systemic treatment given at metastatic disease than the first line therapy with aromatase inhibitor and CDK4\u002F6 inhibitor.\n4. Visceral crisis, per investigator's assessment.\n5. Liver-only metastases.\n6. Prior exposure to any authorized or experimental agent degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc).\n7. Pregnancy or lactation period.\n8. In women of childbearing potential or premenopausal women or women with amenorrhea of less than 12 months, without adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization; LH-RH agonist cannot be considered as an efficient contraceptive measure), positive urinary or serum pregnancy test 72 hours before 18F-FES PET\u002FCT.\n9. Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease. Patients with a history of CNS metastases or cord compression are eligible if they have been treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable and off anticonvulsants and steroids for at least 4 weeks before treatment start.\n10. History of previous cancer or hematological malignancy within 3 years preceding patient enrollment in the trial. Multiple primary breast cancers (controlateral\u002Fipsilateral cancers\u002Flocal relapses) are allowed pending all tumors were ER+ HER2-.\n11. Persons deprived of their freedom or under guardianship or incapable of giving consent.",{"count":177,"type":22},[226],"PHASE3","Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.",[229],"Breast Carcinoma",[231,232,233],"Metastatic","PET\u002FCT 18F-FES","Circulating markers","2026-04-16",{"date":207,"type":34},{"date":237,"type":34},"2024-05-27",{"date":239,"type":22},"2030-09-27",{"name":40,"class":41},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":192},"100630723","validation-of-capillary-microsampling-for-therapeutic-drug-monitoring-of-cdk46-inhibitors-in-breast-cancer-patients-tdhome-100630723","NCT07491380","Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4\u002F6 Inhibitors in Breast Cancer Patients (TDHOME)","Validation of Capillary Microsampling for Therapeutic Drug Monitoring (TDM) of CDK4\u002F6 Inhibitors in Breast Cancer Patients","TDHOME","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years) with breast cancer.\n2. Patients currently receiving ribociclib, abemaciclib, or palbociclib.\n3. Patients capable of performing capillary sampling (with or without assistance).\n4. Patient information and signing of informed consent.\n5. Patient ability to comply with protocol requirements.\n6. Patients covered by a health insurance system.\n\nExclusion Criteria:\n\n1. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.\n2. Persons deprived of their liberty or under guardianship.",{"count":250,"type":22},90,[25],"This is a prospective validation study, multicenter, open-label, single-arm study, evaluating the concordance between capillary microsampling (using the VAMS Mitra device) and venous sampling in patients undergoing CDK4\u002F6 therapy.",[254],"Breast Cancer",[256],"Capillary microsampling, therapeutic drug monitoring, ribociclib, abemaciclib, palbociclib, breast cancer, pharmacokinetics, personalized treatment","2026-04-13",{"date":234,"type":34},{"date":260,"type":22},"2026-05-15",{"date":262,"type":22},"2028-12-15",{"name":40,"class":41},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":140},"100566786","phase-2-cutting-edge-imaging-with-pet-fapi-for-earlier-pancreatic-cancer-diagnosis-indigo-fapi-100566786","NCT06659705","Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)","INDIGO-FAPI","Inclusion Criteria:\n\n1. Cyto\u002Fhistologically proven PDAC\n2. Non-metastatic proven PDAC on recent (\\\u003C 1 month) CT-scan and MRI\n3. Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)\n4. Age \\> 18 years old\n5. Affiliation to a social security scheme\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Protected adults (guardianship, curatorship or safeguarding justice)\n2. Pregnant or breastfeeding woman\n3. Women of childbearing potential not using one highly effective method of contraception",{"count":273,"type":22},35,[275],"PHASE2","Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening.\n\nIn addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process.\n\nAll study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared.\n\nPatient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.",[278],"Pancreatic Ductal Adenocarcinoma (PDAC)",[280,281,282,283,284],"Fibroblast Activation Protein Inhibitor","Positron Emission Tomography","Pancreatic ductal adenocarcinoma","PDAC","FAPI","2026-04-10",{"date":287,"type":34},"2026-04-15",{"date":289,"type":34},"2025-12-02",{"date":291,"type":22},"2030-08-08",{"name":40,"class":41},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":192},"100446050","analysis-of-circulating-tumor-markers-in-blood-4---alcina-4-100446050","NCT05088395","Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","ALCINA4","Inclusion Criteria:\n\n* Patient treated for cancer at one of the participating center\n* 18 years old or higher\n* Signed informed consent form\n* Patient not deprived of their liberty or under guardianship (including temporary guardianship)\n* Patient covered by social security scheme\n* Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up\n* Other additional criteria will be defined (defining tumor type and clinical setting), by cohort\n\nIf a biopsy tumor sample is to be taken:\n\n* Tumor considered as accessible by biopsy (at the investigator's discretion).\n* Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion).\n* No anticoagulant or antiaggregant treatment for the biopsy.\n\nExclusion Criteria :\n\nPregnant and\u002For breast-feeding women depending on cohort.",{"count":301,"type":22},2050,[25],"Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort.\n\nDepending on the clinical context studied and the biomarkers studied and\u002For sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.",[181],[306,307],"circulating biomarkers","Cohort","2026-04-09",{"date":310,"type":34},"2026-04-14",{"date":312,"type":34},"2022-05-19",{"date":314,"type":22},"2031-06-01",{"name":40,"class":41},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},"100607810","phase-2-tucatinib-and-trastuzumab-in-her3-mutant-and-her2-not-amplified-metastatic-breast-cancer-100607810","NCT07193394","Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer","Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer: a Proof of Concept Study (H3RAKLES)","H3RAKLES","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Metastatic or unresectable breast cancer\n* HER2-negative (defined as having an IHC 0+, IHC 1+, or IHC 2+ and ISH non-amplified, per ASCO\u002FCAP guidelines) on last assessable tumor sample\n* Having received ≥ 2 previous chemotherapy lines for advanced breast cancer: including at least one line of conjugated antibody, at the investigator's discretion or if a germinal BRCA mutation is present, a PARP inhibitor.\n* Class IV or V somatic ERBB3 mutation as determined on a tumor sample obtained during the molecular screening step\n* ECOG performance status ≤ 2 (Appendix A)\n* Evaluable disease, per RECIST v1.1 inclusion criteria\n* Left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study treatment\n* Adequate organ function:\n\n  1. Creatinine clearance ≥ 50 mL\u002Fmin as calculated per institutional guidelines\n  2. Total bilirubin ≤1.5 X upper limit of normal (ULN), except for patients with known Gilbert's disease, who may enroll if the conjugated bilirubin is ≤1.5 X ULN.\n  3. Transaminases (aspartate aminotransferase and alanine aminotransferase) ≤ 2.5 X ULN (≤ 5 X ULN if the patient has liver metastases)\n* Women of childbearing potential (WCBP) must have a negative serum pregnancy test \\\u003C 7 days prior to first dose of treatment. A woman is considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as the absence of menses for 12 months without an alternative cause.\n* WCBP (as defined above) and men with partners of childbearing potential must agree to use a highly effective birth control method during the study and for 3 months after completion of investigational treatment.\n* Patients should be eligible for the treatment step according to the investigator's opinion.\n* Patients must be covered by a health insurance plan.\n* Patients able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Having received any prior treatment targeting HER2. Prior treatment with trastuzumab deruxtecan is allowed, per label, in patients with HER2-low metastatic breast cancer (IHC 1+ or 2+, ISH non-amplified)\n* History of allergic reactions to trastuzumab or tucatinib or chemically similar drugs\n* Patients who are pregnant, breastfeeding, or planning a pregnancy from time of informed consent until 7 months after the final dose of study drug\n* Inability to swallow pills or having a significant gastro-intestinal disease or a history of surgery which would preclude the adequate oral absorption of medications\n* Having used a strong CYP2C8 inhibitor within a duration of 5 half-lives prior to the first dose of study treatment, or have used a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment (see Appendix B and Appendix C)\n* Treatment with any systemic anti-cancer therapy (including hormonal therapy), non-central nervous system (CNS) radiation, or experimental agent ≤ 3 weeks prior to the first dose of study treatment, except gonadotropin releasing hormone (GnRH) agonists\n* Participation in another interventional clinical trial.\n* Symptomatic and untreated brain metastases or brain metastases requiring urgent treatment, or brain metastases requiring a dose \\> 2 mg of dexamethasone (or equivalent)\n* Whole brain radiotherapy \\\u003C 21 days prior to first dose of treatment, stereotactic radiotherapy \\\u003C 7 days prior to first dose of treatment\n* Leptomeningeal metastases\n* Major surgery (including surgery of brain metastases) \\\u003C 21 days prior to first dose of treatment\n* Evidence within 2 years of the start of study treatment of another malignancy that required systemic treatment\n* Have known myocardial infarction or unstable angina within 24 weeks prior to first dose of study treatment\n* Have clinically significant cardiopulmonary disease such as:\n\n  * Ventricular arrhythmia requiring therapy,\n  * Uncontrolled hypertension (defined as persistent systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\> 100 mm Hg on antihypertensive medications)\n  * Any history of symptomatic congestive heart failure\n  * Severe dyspnea at rest (CTCAE v5.0 Grade 3 or above) due to complications of advanced malignancy\n  * Hypoxia requiring supplementary oxygen therapy except when oxygen therapy is needed only for obstructive sleep apnea\n  * Presence of ≥ Grade 2 QTc prolongation on screening ECG\n* Conditions potentially resulting in drug-induced prolongation of the QT interval or torsade de pointes:\n\n  * Congenital or acquired long QT syndrome\n  * Family history of sudden death\n  * History of previous drug-induced QT prolongation\n  * Current use of medications with known and accepted associated risk of QT prolongation (see row \"Accepted Association\" in Appendix D)\n* Are known carriers of active Hepatitis B or Hepatitis C or have other known chronic liver disease\n* Are known to be positive for human immunodeficiency virus (HIV)\n* Altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.\n* Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons\n* Person deprived of liberty or under guardianship",{"count":325,"type":22},20,[275],"The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy. Patients included in this trial will have already received at least two lines of chemotherapy (and potentially several lines of endocrine therapy for patients with a HR+ disease). In this setting, few treatments have demonstrated a clinically meaningful benefit, and any additional option is valuable. Furthermore, the pre-clinical and clinical rationale indicate a high probability of clinical benefit, as previously shown in Table 1, with all patients treated with trastuzumab and a TKI targeting HER2 displaying a response. Besides, with several years of hindsight for the combination of lapatinib, trastuzumab and capecitabine, we expect excellent tolerance with the same treatment without capecitabine.\n\nThe H3RAKLES single-arm phase II trial will evaluate the combination of tucatinib, a HER2 TKI, and trastuzumab, a HER2-directed antibody in patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation. To demonstrate the actionability of ERBB3 mutations, all patients will receive a combination of trastuzumab and tucatinib, in 3-weeks cycles.",[329,330],"Metastatic Breast Cancer ( HER2 Negative)","Unresectable Breast Cancer",[332,181,333,334,335,336,337,338],"Breast","HER2","tucatinib","trastuzumab","HER3","metastatic","unresectable","2026-02-20",{"date":341,"type":34},"2026-02-23",{"date":343,"type":22},"2026-01-31",{"date":345,"type":22},"2029-06-08",{"name":40,"class":41},9,{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":373},"100499287","multicentre-randomised-study-comparing-a-taurolidine-lock-and-a-standard-saline-lock-in-paediatric-oncology-100499287","NCT05781295","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.","PEDIALOCK","Inclusion Criteria:\n\n1. Patient less than or equal to 21 years of age at inclusion.\n2. Patient for whom a central catheter is planned to be inserted\\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \\*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).\n3. Patient treated for a cancer.\n4. Patient with regular follow-up in the inclusion center.\n5. Informed consent signed by the patient if adult or by legal representatives if minor.\n6. Patient benefiting from a social security coverage.\n7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.\n\nExclusion Criteria:\n\n1. Patient with retinoblastoma.\n2. Allografted patient.\n3. Patient with a life expectancy of less than 6 months.\n4. Patient refusing to participate in the protocol.\n5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).\n6. Patient with known allergy to citrate or (cyclo)-Taurolidine.\n7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.\n8. Patient with an external femoral catheter.\n9. Patient with a PICCLINE-type peripheral venous inserted central catheter.\n10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.\n11. Patient under guardianship and curatorship.","21 Years",{"count":358,"type":22},148,[25],"Interest of a Taurolidine lock at each catheter closure in the primary prevention of catheter-related endoluminal infection in paediatric oncology.\n\nMulticentric, controlled, randomized and double-blind label study.",[362,363,364,365],"Children","Medical Device","Primary Prevention","Oncology","2026-02-18",{"date":339,"type":34},{"date":369,"type":34},"2024-01-19",{"date":371,"type":22},"2028-07-23",{"name":40,"class":41},5,{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":392,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},"100287124","prospective-biobanking-study-in-cancer-patients-aiming-at-better-understand-the-link-between-the-molecular-alterations-of-the-tumor-itself-its-microenvironment-and-immune-response-scandare-100287124","NCT03017573","Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)","SCANDARE","Inclusion Criteria:\n\n1. Tumor types :\n\n   1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy\n   2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy\n   3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery\n   4. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).\n   5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment\n2. Male or female patients ≥ 18 years of age\n3. Signed informed consent\n\nExclusion Criteria:\n\n1. Male or female patients ≤18 years old\n2. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n3. Individually deprived of liberty or placed under the authority of a tutor\n4. Patients not affiliated to the Social Security System",{"count":382,"type":22},1050,[25],"SCANDARE is a prospective biobanking study on tumor (+\u002F- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and\u002For immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.",[386,387,388,389,390,391],"Ovarian Cancer","Triple-Negative Breast Cancer","Head and Neck Cancer","Cervical Cancer","Sarcoma","Vulva Cancer",[393,394,395],"Immunological biomarkers","molecular profil","Circulating tumor DNA (ctDNA)","2026-01-30",{"date":398,"type":34},"2026-02-03",{"date":400,"type":34},"2017-01-06",{"date":402,"type":22},"2032-01-06",{"name":40,"class":41},6,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":427},"100472985","phase-3-opioid-free-versus-opioid-based-anaesthesia-for-free-flap-reconstruction-surgery-of-the-breast-a-phase-iii-multicentric-randomized-controlled-study-100472985","NCT05439005","Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.","OFOBA","Inclusion Criteria:\n\n1. Women aged 18 or older.\n2. Patients with a French health insurance coverage (having a French social security number).\n3. Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia.\n4. Patient who has given written consent to participate in accordance with the regulations.\n5. Having a negative blood pregnancy test for patients of childbea ring age.\n\nExclusion Criteria:\n\n1. Allergy or intolerance to any of the drugs (dexmedetomidine, remifentanil, lidocaine, propofol, dexamethasone, kétamine, ketoprofen, nefopam, paracetamol, morphine, ropivacaine, droperidol, ondansetron).\n2. Known history of heart failure, arrhythmias and\u002For ischemic heart disease and\u002For severe renal insufficiency.\n3. Pulse below 50bpm during anaesthesia consultation and\u002For under beta blocker treatment.\n4. Treatment with ACEI\u002FARB.\n5. Severe asthma.\n6. Symptomatic gastric or duodenal ulcer with or without treatment.\n7. Baseline systolic blood pressure \\\u003C 100 mmHg.\n8. Chronic preoperative pain and\u002For use of WHO ladder step 2 or 3 analgesics preoperatively.\n9. Patient already included in another therapeutic trial evaluating an experimental molecule.\n10. Persons deprived of liberty or under guardianship.\n11. Patients with suspected difficulties in assessing pain on a scale.\n12. Inability to undergo trial medical monitoring due to geographic, social or psychological reasons.",{"count":413,"type":22},158,[226],"This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.",[254],[418,419],"free flap reconstruction surgery","anaesthesia","2026-01-28",{"date":396,"type":34},{"date":423,"type":34},"2022-12-07",{"date":425,"type":22},"2027-06-06",{"name":40,"class":41},3,{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":427},"100551415","efficacy-of-personalized-tumorogram-based-therapy-in-cancer-established-from-patient-derived-organoid-avatar-100551415","NCT06459791","Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)","Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Biological Avatar: Proof-of-concept Study","AVATAR","Inclusion Criteria:\n\n1. Patient over 18 years of age\n2. Advanced breast cancer\n3. Triple-negative phenotype (HR-\u002FHER2-) or HR+\u002FHER2- after hormone resistance (progression after treatment with hormone therapy + CDK4\u002F6 inhibitor)\n4. Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy\n5. Performans Status 0-1\n\nExclusion Criteria:\n\n1. More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy\u002FCDK4\u002F6 inhibitor)\n2. Progressive brain metastases\n3. Leptomeningeal metastasis",{"count":437,"type":22},110,[25],"A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.",[441],"Metastatic Breast Cancer",[443,444,445,446,447],"tumorogram","metastatic breast cancer","avatar","Organoid","PDO","2026-01-27",{"date":450,"type":34},"2026-01-29",{"date":452,"type":34},"2024-12-06",{"date":454,"type":22},"2028-09-30",{"name":40,"class":41},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":140},"100620414","screening-and-care-for-fear-of-cancer-recurrence-in-patients-with-cancer-at-institut-curie-100620414","NCT07357311","Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie","Fear of Cancer Recurrence: Prevalence, Lived Experience and Satisfaction of Supportive Care Needs in the Hospital Care Pathway. A Mixed Method Study.","PDR-CARE","Inclusion Criteria:\n\n* Aged 18 or over\n* Clinical or pathological diagnosis of primary or recurrence of a localized\u002Floco-regional or metastatic breast cancer, or a stage 1 or 2, or stage 3 or 4 lung cancer; or a breast or lung cancer metastatic progression\n* Three months after completing treatment or three months after the start of a first treatment line for metastatic progression\n* Able to comply with the scheduled assessment and interviews\n* Able to read and understand the questionnaires' language (i.e. French)\n\nExclusion Criteria:\n\n* Participating in another patient-reported outcome study interfering with the present study\n* Any social, medical or psychological condition hindering questionnaire completion\n* Being deprived of personal liberty or under guardianship",{"count":465,"type":22},200,"The goals of this study is to establish the prevalence of severe forms of FCR in the oncology hospital setting, which will require a specific psychotherapeutic response. Two cancer sites are targeted: breast and pulmonary cancers. Secondary objectives include: 1) Determining threshold scores for the FCRI's 9-item severity scale for each type of cancer; 3) To identify a simple item from the FCRI for early detection of FCR in everyday clinical practice, especially using a digital format.",[468,254],"Lung Cancer",[470,471,472,473],"FCR","FoP","Lung cancer","Breast cancer","2026-01-21",{"date":476,"type":34},"2026-01-23",{"date":478,"type":34},"2025-09-08",{"date":480,"type":22},"2027-12-31",{"name":40,"class":41},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":507},"100533414","early-detection-of-triple-negative-breast-cancer-relapse-cupcake-100533414","NCT06225505","Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial","CUPCAKE","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent before inclusion\n2. Patients must be female ≥ 18 years old\n3. Patients diagnosed with a non-metastatic TNBC (ER \\& PR \\\u003C10%, HER2- per ASCO\u002FCAP guidelines). Patients must have been previously evaluated by a 18F-FDG PET-CT or a bone scintigraphy combined with a thorax, abdomen and pelvis CT scan with contrast\n4. Patients who have undergone surgery with curative intent for their non-metastatic TNBC. Surgery must have been performed between 3 to 9 months before inclusion. Patients must have initiated their adjuvant therapy, whenever indicated, since at least 12 weeks. For patients receiving an experimental adjuvant treatment in a clinical trial, any intervention planned as part of this trial must be completed before inclusion.\n5. High-risk primary tumor, defined as:\n\n   1. Lack of pathological complete response after neoadjuvant chemotherapy (RCB I, II or III; RCB I being capped to a maximum of 30% of included patients) OR, in the absence of neoadjuvant chemotherapy,\n   2. Stage IIB-III (i.e., T2N1, any T3-T4, any N2-3) OR\n   3. Any loco-regional relapse occurring after a prior ipsilateral, curatively treated TNBC\n6. No sign of local or distant relapse, as per investigator assessment\n7. Performance status \\\u003C 2\n8. Available FFPE tumor block with \\> 10% cellularity or 11 tumor sections with \\>10% cellularity\n9. Patient able to comply with protocol requirements\n10. Patients covered by a health insurance\n\nExclusion Criteria:\n\n1. Any uncontrolled disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding or any other medical condition that, in the opinion of the investigator, interferes with the trial procedures\n2. Male participants\n3. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.\n4. Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons\n5. Person deprived of liberty or under guardianship\n6. History of another primary malignancy except for the following :\n\n   1. Basal cell carcinoma or any in situ carcinoma treated with curative intent\n   2. Any stage I-II malignancy treated with curative intent with no evidence of active disease in the last five years\n7. For step #2 (randomization after ctDNA detection): clinical\u002Fradiological metastatic relapse before the detection of the molecular relapse.",{"count":491,"type":22},450,[25],"CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse.\n\nThe study has two steps. In Step 1, patients who have completed the treatments for a localized TNBC will undergo ctDNA monitoring every \\~4 months (± 2 weeks). In Step 2, patients for whom ctDNA will be detected will then be randomized between an observation arm, in which monitoring will continue until the detection of a clinical relapse, and an experimental arm, in which the ctDNA detection will be revealed to both the patient and the clinician: patients will then undergo a 18F-FDG PET-CT and a 68Ga-FAPI-46-PET-CT, in addition to whatever workup the investigator will deem necessary.",[28],[496,497,498],"Triple negative breast cancer","68Ga-FAPI-46","ctDNA","2026-01-20",{"date":501,"type":34},"2026-01-22",{"date":503,"type":34},"2026-01-05",{"date":505,"type":22},"2031-08-03",{"name":40,"class":41},13,{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":404},"100542949","68ga-fapi-46-petct-for-predicting-histological-response-in-triple-negative-breast-cancer-fap-it-100542949","NCT06349512","68Ga-FAPI-46 PET\u002FCT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)","68Ga-FAPI-46 PET\u002FCT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer","FAP-IT","Inclusion Criteria:\n\n1. Female with age ≥ 18 years,\n2. Patients with previously untreated, non-metastatic, centrally confirmed TNBC for whom a neoadjuvant treatment with chemotherapy + pembrolizumab is the recommended option as standard of care,\n3. Patients with measurable targets according to RECIST\u002FPERCIST criteria,\n4. Patients without distant metastasis based on staging 18F-FDG PET\u002FCT,\n5. Patients with tumor tissue available,\n6. Patients who provided a signed written informed consent,\n7. Patient ability to comply with protocol requirements,\n8. Patients covered by a health insurance system.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women,\n2. Patients with prior anti-PD(L)1 immunotherapy,\n3. Patients with any contra-indication to chemo-immunotherapy standard of care therapy, per investigator assessment,\n4. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent,\n5. Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons,\n6. Person deprived of liberty or under guardianship",{"count":517,"type":22},60,[25],"Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET\u002FCT imaging in patients with early-stage high-risk TNBC.",[28],"2025-12-15",{"date":523,"type":34},"2025-12-22",{"date":525,"type":34},"2024-10-14",{"date":527,"type":22},"2032-11-30",{"name":40,"class":41},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":51,"minAge":537,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":5},"100414807","phase-2-ocular-conservative-treatment-for-retinoblastoma--efficacy-of-the-new-management-strategies-and-visual-outcome-100414807","NCT04681417","Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018","RETINO 2018","Inclusion Criteria:\n\nOverall study inclusion criteria:\n\n1. Newly diagnosed retinoblastoma (RB).\n2. Retinoblastoma with at least one eye eligible for conservative management.\n3. Patients likely to be compliant with the study requirements and visits, including late follow-up.\n4. Patients not previously treated with chemotherapy or radiotherapy for this or any other cancer.\n5. Patients with no contraindication to the proposed treatments.\n6. Informed consent signed by parents or legal representative.\n7. French Social Security System coverage.\n\nStudy 1 inclusion criteria:\n\n8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed manageable with IAC in one side and without IV chemotherapy:\n\n1. Unilateral Retinoblastoma classified as group B, C (if vitreous seeds \\\u003C 3 mm), D or E with no invasion of the anterior segment, and without massive tumor of more than 2\u002F3 of the eye, eligible for conservative management, or\n2. Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one eye group D or E without invasion of the anterior segment or massive tumor of more than 2\u002F3 of the eye, eligible for IAC, and the other eye eligible for local treatment only (without IAC).\n\nStudy 2 inclusion criteria:\n\n8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:\n\n1. Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B, C or D, with or without vitreous seeding, compatible with conservative management, or\n2. Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the anterior segment, and\u002For massive tumors of more than 2\u002F3 of the eye and eligible for conservative management.\n\nExclusion Criteria:\n\nOverall study non-inclusion criteria:\n\n1. RB not eligible for conservative management :\n\n   1. Extra-ocular extension of the disease, or\n   2. Group E eyes with invasion of the anterior segment, and\u002For massive tumors of more than 2\u002F3 of the eye.\n2. Patient older than 6 years of age.\n3. Patients with another associated disease contra indicating systemic chemotherapy.\n4. Previously treated retinoblastoma by chemotherapy.\n5. Patients already treated for another malignant disease.\n6. Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n7. Patients whose parents have not accepted the treatment regimen after explanation of it.\n8. Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics) of the study drugs.\n9. Inclusion in another experimental anti-cancer drug therapy.\n\n   Study 1 non-inclusion criteria:\n10. Any contraindication or concomitant disease that would preclude the Study 1 treatment procedure and could delay treatment.\n\nThese patients should be eligible for Study 2.","6 Months","6 Years",{"count":540,"type":22},225,[275,226],"This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:\n\n* Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.\n* Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.",[544],"Retinoblastoma",[546,547],"Pediatric","Ocular conservative treatment in retinoblastoma","2025-11-21",{"date":550,"type":34},"2025-11-28",{"date":552,"type":34},"2021-03-25",{"date":554,"type":22},"2036-01-20",{"name":40,"class":41},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":427},"100423194","liquid-biopsy-to-predict-responses-to-first-line-immunotherapy-in-metastatic-non-small-cell-lung-cancer-liberty-lung-100423194","NCT04790682","LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG","LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer","LIBERTYLUNG","Inclusion Criteria:\n\n1. Histologically-proven NSCLC.\n2. Age ≥ 18 years.\n3. Advanced or metastatic stage IV.\n4. Treatment-naïve patient.\n5. Eligibility to first-line treatment with immune checkpoint inhibitor.\n6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.\n7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.\n8. No ALK or EGFR gene alteration.\n9. Availability of tumor tissue for NGS analysis (7 slides).\n10. PS 0 or 1.\n11. Signed informed consent of the patient.\n\nExclusion Criteria:\n\n1. No social security affiliation.\n2. Person under legal protection.\n3. Pregnant and breastfeeding women.\n\nPatients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy\u002Fchemotherapy treatment nor study follow-up ; after investigator's information",{"count":177,"type":22},[25],"Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.",[568],"Metastatic Lung Cancer",[570,571,572],"Lung Cancer NSCLC","metastatic stage","first-line treatment with immunotherapy","2025-09-17",{"date":575,"type":34},"2025-09-18",{"date":577,"type":34},"2021-05-22",{"date":579,"type":22},"2030-06-03",{"name":40,"class":41},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":51,"minAge":589,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":427},"100601486","phase-2-comparison-of-18f-labeled-analog-of-mibg-18f-mfbg-petct-and-123i-mibg-spect-in-pediatric-patients-with-neuroblastoma-100601486","NCT07111117","Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET\u002FCT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.","Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET\u002FCT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma","NEUROBLASTOTEP","Inclusion Criteria:\n\n1. Patients with histologically proven neuroblastoma.\n2. Relapsed or refractory neuroblastoma.\n3. 123I-MIBG avid neuroblastoma (positive 123I-MIBG scintigraphy = showing at least one neuroblastoma lesion (either primary or metastatic) with a significant avidity for 123I-MIBG), performed within 2 weeks to 2 days prior to 18F-MFBG PET\u002FCT.\n4. No specific treatment for neuroblastoma between 123I-MIBG scintigraphy and 18F-MFBG PET\u002FCT (PET\u002FCT shall not delay therapeutic management.)\n5. Age ≥ 365 days to \\\u003C 18 years old. For children under 13 months, day of birth should be collected.\n6. Weight ≥ 9 kg.\n7. Performance Status: Lansky or Karnofsky ≥ 60%.\n8. Signed written informed consent by the 2 holders of the parental authority or legal representative(s).\n9. Patients covered by a health insurance system.\n\nExclusion Criteria:\n\n1. Patient inability to comply with protocol requirements without general anesthesia.\n2. Pregnant or breastfeeding patient. If indicated, at the investigator's discretion, patients of childbearing potential should have urinary pregnancy test the day of the PET\u002FCT procedure, prior to the MFBG administration.\n3. Any treatment likely to interact with MIBG initiated\u002Fmodified between scintigraphy with MIBG and PET\u002FCT with MFBG.\n4. Patient with a parent or legal representative with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid informed consent","365 Days","17 Years",{"count":592,"type":22},30,[275],"The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography \u002F Computed Tomography scan (PET\u002FCT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.",[596],"Neuroblastoma",[596,598,599,600],"PET \u002F CT","Imaging","Radiotracer","2025-09-02",{"date":603,"type":34},"2025-09-03",{"date":605,"type":22},"2026-03-01",{"date":607,"type":22},"2028-09",{"name":40,"class":41},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":23,"phases":619,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":427},"100482178","characterisation-of-the-immune-infiltrate-and-molecular-features-of-thymic-epithelial-tumors-tumors-tets-immuno-tet-100482178","NCT05558644","Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)","Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)","IMMUNO-TET","Inclusion Criteria:\n\n1. Patient with suspicion of localised thymic epithelial tumour.\n2. Age ≥ 18 years.\n3. Treatment-naïve patient for this disease.\n4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers.\n5. Signed informed consent form of the patient.\n\nExclusion Criteria:\n\n1. Neoadjuvant chemotherapy.\n2. No social security affiliation.\n3. Person under legal protection.\n4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).",{"count":618,"type":22},50,[25],"The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).",[181],[623],"thymic epithelial tumors",{"date":478,"type":34},{"date":626,"type":34},"2023-08-03",{"date":628,"type":22},"2026-10-05",{"name":40,"class":41},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":23,"phases":639,"briefSummary":640,"conditions":641,"keywords":643,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":140},"100395103","follow-up-of-patients-with-uveal-melanoma-adapted-to-the-risk-of-relapse-salome-100395103","NCT04424719","Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)","SALOME","Inclusion Criteria:\n\n1. Patient aged of 18 years or more.\n2. Patient with uveal melanoma with high metastatic relapse risk defined as :\n\n   * T2b\u002Fc\u002Fd ou ≥ T3,\n   * or chromosom 3 or chromosom 8 abnormality by CGH array.\n3. Completion of treatment of the primary tumor ≤ 2 months.\n4. Patient able to comply with the schedule of visits and blood samples of the study.\n5. Signed informed consent form or legal representative.\n\nExclusion Criteria:\n\n1. Patient without french social insurance.\n2. Any social, medical or psychological condition making the research process impossible.",{"count":638,"type":22},700,[25],"Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.",[642],"Uveal Melanoma",[644],"uveal melanoma",{"date":603,"type":34},{"date":647,"type":34},"2020-07-08",{"date":649,"type":22},"2037-07-07",{"name":40,"class":41},{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":117,"enrollmentInfo":658,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":659,"conditions":660,"keywords":662,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":427},"100605158","skin-reactions-related-to-thoracic-implantable-chamber-dressings-100605158","NCT07158879","Skin Reactions Related to Thoracic Implantable Chamber Dressings","KPAREAC","Inclusion Criteria:\n\n* Patients over 18 years of age\n* New chemotherapy patients (1st line of treatment only)\n* Thoracic PAC\n\nExclusion Criteria:\n\n* PICC Line and femoral PAC;\n* Patients undergoing treatment with bi-specific antibodies (e.g. tebentafusp);\n* Disunion requiring treatment\n* Patients treated for hematological cancer;\n* Persons deprived of their liberty or under guardianship (including curatorship);\n* Adults under court protection;\n* Inability to participate in the study for geographical, social or psychological reasons.\n* No inclusion of persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.).\n* Opposition to data use",{"count":55,"type":22},"Prospective, multicenter cohort of 500 patients newly treated with systemic chemotherapy with CCI. The main objective of this study is to measure the incidence of skin reactions related to thoracic implantable chamber dressings.",[661],"Skin Diseases",[663,664,665],"cancers treated with chemotherapy","skin reaction","dressings","2025-08-28",{"date":478,"type":34},{"date":669,"type":34},"2025-06-10",{"date":671,"type":22},"2026-12-10",{"name":40,"class":41},""]